{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:07:45Z","timestamp":1791943665749,"version":"4.3.4"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008136","name":"CWRU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bcp.2019.02.033","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T12:35:45Z","timestamp":1551357345000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"special_numbering":"C","title":["Inhibition of MMPs and ADAM\/ADAMTS"],"prefix":"10.1016","volume":"165","author":[{"given":"Charles J.","family":"Malemud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.02.033_b0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/A:1005722729132","article-title":"Matrix metalloproteinase inhibitors","volume":"15","author":"Wojowcitz-Praga","year":"1997","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2019.02.033_b0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/1568009053765799","article-title":"Matrix metalloproteinases as therapeutic targets in cancer","volume":"5","author":"Vihinen","year":"2005","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2019.02.033_b0015","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2174\/156800908786733478","article-title":"ADAM proteins \u2013 therapeutic potential in cancer","volume":"8","author":"Lu","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2019.02.033_b0020","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2174\/187152012802650200","article-title":"Introduction: MMPs, ADAMs\/ADAMTSs research products to achieve big dreams","volume":"12","author":"Okazaki","year":"2012","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0025","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.2174\/1389450117666160727143618","article-title":"Targeting ADAM17 sheddase activity in cancer","volume":"17","author":"Rossello","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bcp.2019.02.033_b0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/17460441.2018.1398732","article-title":"Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer","volume":"13","author":"Zhong","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bcp.2019.02.033_b0035","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/ard.61.11.975","article-title":"Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10","volume":"61","author":"Tolboom","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.02.033_b0040","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s13075-014-0429-9","article-title":"Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis","volume":"16","author":"Dancevic","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2019.02.033_b0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/bs.pmbts.2017.03.002","article-title":"Metalloproteinases in rheumatoid arthritis: potential therapeutic targets to improve current therapies","volume":"148","author":"Itoh","year":"2017","journal-title":"Prog. Mol. Biol. Trans. Sci."},{"key":"10.1016\/j.bcp.2019.02.033_b0050","first-page":"133","article-title":"Proteases involved in cartilage degradation in osteoarthritis","volume":"1824","author":"Troeberg","year":"2012","journal-title":"BBA"},{"key":"10.1016\/j.bcp.2019.02.033_b0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/BOR.0000000000000162","article-title":"Biological basis of osteoarthritis: state of the evidence","volume":"27","author":"Malemud","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"issue":"7","key":"10.1016\/j.bcp.2019.02.033_b0060","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.joca.2017.02.791","article-title":"ADAMTS and ADAM metalloproteinases in osteoarthritis \u2013 looking beyond the \u2018usual suspects\u2019","volume":"25","author":"Yang","year":"2017","journal-title":"Osteoarthrit. Cartil."},{"key":"10.1016\/j.bcp.2019.02.033_b0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.bcp.2019.02.033_b0070","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/BOR.0b013e32805e87e0","article-title":"The role of T cells in rheumatoid arthritis: new subsets and new targets","volume":"19","author":"Toh","year":"2007","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.imlet.2006.04.011","article-title":"Molecular and cellular basis of rheumatoid arthritis destruction","volume":"106","author":"Karouzakis","year":"2006","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.bcp.2019.02.033_b0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cca.2016.02.010","article-title":"Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis","volume":"455","author":"Mateen","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bcp.2019.02.033_b0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00281-017-0633-1","article-title":"Cellular and molecular perspectives in rheumatoid arthritis","volume":"39","author":"Veale","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bcp.2019.02.033_b0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.rdc.2010.02.006","article-title":"Targeting IL-17 and Th17 cells in rheumatoid arthritis","volume":"36","author":"Sarkar","year":"2010","journal-title":"Rheum. Dis. Clin. N Am."},{"key":"10.1016\/j.bcp.2019.02.033_b0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.rdc.2010.02.004","article-title":"Cell-cell interactions in rheumatoid arthritis synovium","volume":"36","author":"Fox","year":"2010","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.bcp.2019.02.033_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/950192","article-title":"Aging and osteoarthritis: an inevitable encounter?","volume":"2012","author":"H\u03cbgle","year":"2012","journal-title":"J. Aging Res."},{"key":"10.1016\/j.bcp.2019.02.033_b0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000070573","article-title":"Pathophysiologic mechanisms in osteoarthritis lead to novel therapeutic strategies","volume":"174","author":"Malemud","year":"2003","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.bcp.2019.02.033_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/joca.2001.0488","article-title":"Osteoarthritis or osteoarthrosis: the definition of inflammation becomes semantic in the era of molecular medicine","volume":"10","author":"Attur","year":"2002","journal-title":"Osteoarthritis Cartil."},{"key":"10.1016\/j.bcp.2019.02.033_b0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clim.2012.12.011","article-title":"Immunopathogenesis of osteoarthritis","volume":"146","author":"Haseeb","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bcp.2019.02.033_b0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2217\/17460816.3.3.253","article-title":"Is there a final common pathway for arthritis?","volume":"3","author":"Malemud","year":"2008","journal-title":"Future Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0125","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.2174\/13816128113196660701","article-title":"Metalloproteinases and metalloproteinase inhibitors in age-related diseases","volume":"20","author":"Gargiulo","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"12","key":"10.1016\/j.bcp.2019.02.033_b0130","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1002\/jcb.23298","article-title":"ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis","volume":"112","author":"Verma","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2019.02.033_b0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/toxins8040122","article-title":"A disintegrin and metalloprotease (ADAM): historical overview of their functions","volume":"8","author":"Giebeler","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.bcp.2019.02.033_b0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/jfmk2030027","article-title":"A role for soluble IL-6 receptor in osteoarthritis","volume":"2","author":"Akeson","year":"2017","journal-title":"J. Funct. Morphol. Kinesiol."},{"key":"10.1016\/j.bcp.2019.02.033_b0145","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/art.33450","article-title":"Contribution of matrix metalloproteinase 2 to joint destruction in group B Streptococcus-induced murine arthritis","volume":"64","author":"Puliti","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.02.033_b0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/bs.pmbts.2017.03.003","article-title":"Matrix metalloproteinases and synovial joint pathology","volume":"148","author":"Malemud","year":"2017","journal-title":"Prog. Mol. Biol. Trans. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2019.02.033_b0155","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.mam.2008.08.001","article-title":"The ADAM metalloproteinases","volume":"29","author":"Edwards","year":"2008","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bcp.2019.02.033_b0160","doi-asserted-by":"crossref","first-page":"33179","DOI":"10.1074\/jbc.M111.337063","article-title":"Osterix regulates calcification and degradation of chondrogenic matrices through matrix metalloproteinase 13 (MMP13) expression in association with transcription factor Runx2 during endochondral ossification","volume":"287","author":"Nishimura","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0165","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1160\/TH17-06-0379","article-title":"Platelets contribute to the accumulation of matrix metalloproteinase type 2 in synovial fluid in osteoarthritis","volume":"117","author":"Alunno","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcp.2019.02.033_b0170","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.2174\/138161209788682352","article-title":"ADAM19\/adamalysin 19 structure, function and role as putative target in tumors and inflammatory diseases","volume":"15","author":"Qi","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2019.02.033_b0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1021\/pr100556z","article-title":"Active metalloproteases of the a Disintegrin and Metalloprotease (ADAM) family: biological function and structure","volume":"10","author":"Klein","year":"2011","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bcp.2019.02.033_b0180","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.3390\/toxins8050155","article-title":"ADAM and ADAMTS family proteins and snake venom metalloproteases: a structural overview","volume":"8","author":"Takeda","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.bcp.2019.02.033_b0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13059-015-0676-3","article-title":"The ADAMTS (A Disintegrin and Metalloprotease with thrombospondin motifs) family","volume":"16","author":"Kelwick","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.bcp.2019.02.033_b0190","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/801546","article-title":"The function and roles of ADAMTS-7 in inflammatory diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bcp.2019.02.033_b0195","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.matbio.2018.06.002","article-title":"ADAMTS proteins in human disorders","volume":"71\u201372","author":"Mead","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.bcp.2019.02.033_b0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.12016FP","article-title":"In vitro effects of VA441, a new selective cyclooxygenase inhibitor, on human chondrocytes exposed to IL-1\u00df","volume":"120","author":"Fioravanti","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2019.02.033_b0205","doi-asserted-by":"crossref","first-page":"9066","DOI":"10.1074\/jbc.M112.441758","article-title":"Molecular design of highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2)","volume":"288","author":"Higashi","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0210","doi-asserted-by":"crossref","first-page":"22871","DOI":"10.1074\/jbc.M113.462267","article-title":"Activity of ADAM17 (a disintegrin and metalloproteinase 17) is regulated by its noncatalytic domains and secondary structure of substrates","volume":"288","author":"Stawikowska","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0215","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/14756366.2013.855207","article-title":"A novel matrix metalloproteinase-2 inhibitor triazolylmethyl azaridine reduces melanoma cell invasion, angiogenesis and targets ERK1\/2 phosphorylation","author":"Romanchikova","year":"2014","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0220","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/09537104.2016.1203396","article-title":"Considerations of inhibition approaches for proinflammatory functions of ADAM proteases","volume":"28","author":"Dreymueller","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.bcp.2019.02.033_b0225","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1016\/j.bmc.2016.09.009","article-title":"Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors","volume":"24","author":"Nara","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0230","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/cmdc.201700349","article-title":"Recent research advances in selective matrix metalloproteinase-13 inhibitors as anti-osteoarthritis agents","volume":"12","author":"Xie","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2019.02.033_b0235","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3899\/jrheum.121162","article-title":"Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis","volume":"40","author":"Chandran","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2016.03.028","article-title":"Modulation of human monocyte\/macrophage activity by tocilizumab, abatacept and etanercept: an in vitro study","volume":"780","author":"Obeng","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2019.02.033_b0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/14397595.2017.1317320","article-title":"High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab","volume":"28","author":"Hattori","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0250","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/MEG.0b013e3283293d0f","article-title":"Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn\u2019s disease patients treated with infliximab","volume":"21","author":"Di Sabatino","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0255","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/art.39414","article-title":"Selective inhibition of membrane type 1 matrix metalloproteinase abrogates progression of experimental inflammatory arthritis: synergy with tumor necrosis blockade","volume":"68","author":"Kaneko","year":"2016","journal-title":"Arthrit. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0260","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/art.38896","article-title":"Combined inhibition of tumor necrosis factor \u03b1 and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody","volume":"67","author":"Fischer","year":"2015","journal-title":"Arthrit. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0265","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000229021","article-title":"Tocilizumab inhibits interleukin-6-mediated matrix metalloproteinase-2 and -9 secretions from human amnion cells in preterm premature rupture of membranes","volume":"68","author":"Mano","year":"2009","journal-title":"Gynecol. Obstet. Invest."},{"key":"10.1016\/j.bcp.2019.02.033_b0270","doi-asserted-by":"crossref","first-page":"304","DOI":"10.15761\/IMM.1000158","article-title":"Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28\/I2 immortalized human chondrocyte cell line","volume":"2","author":"Meszaros","year":"2015","journal-title":"Integr. Mol. Med."},{"issue":"17","key":"10.1016\/j.bcp.2019.02.033_b0275","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1007\/s00018-012-1214-z","article-title":"Epigenetic regulation of mmp-9 gene expression","volume":"70","author":"Labrie","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2019.02.033_b0280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/2040622312454157","article-title":"Prospects for treating osteoarthritis: enzyme-protein interactions regulating matrix metalloproteinase activity","volume":"3","author":"Meszaros","year":"2012","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.bcp.2019.02.033_b0285","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3892\/or.2013.2548","article-title":"miR-133a suppresses cell proliferation, migration and invasion in human lung cancer by targeting MMP-14","volume":"30","author":"Xu","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2019.02.033_b0290","doi-asserted-by":"crossref","first-page":"E92","DOI":"10.3390\/cells7080092","article-title":"MicroRNAs and osteoarthritis","volume":"7","author":"Malemud","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2019.02.033_b0295","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3892\/mmr.2015.3425","article-title":"Downregulation of matrix metalloproteinase 9 by small interfering RNA inhibits the tumor growth of ovarian epithelial carcinoma in vivo and in vitro","volume":"12","author":"Guo","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bcp.2019.02.033_b0300","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12035-013-8538-z","article-title":"Mmp-9 inhibition: a therapeutic strategy in ischemic stroke","volume":"49","author":"Chaturvedi","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2019.02.033_b0305","doi-asserted-by":"crossref","first-page":"36473","DOI":"10.1074\/jbc.M112.389114","article-title":"Discovery of novel inhibitors of a distintegrin and metalloproteinase 17 (ADAM17) using glycosylated and non-glycosylated substrates","volume":"287","author":"Minond","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0310","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1080\/00365520600684571","article-title":"Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats","volume":"41","author":"Matsumoto","year":"2006","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.bcp.2019.02.033_b0315","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.2174\/138161209788682398","article-title":"ADAM17 as a therapeutic target in multiple diseases","volume":"15","author":"Arribas","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2019.02.033_b0320","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.bmc.2008.11.067","article-title":"Current perspective of TACE inhibitors: a review","volume":"17","author":"DasGupta","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0325","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543770903465157","article-title":"Novel TACE inhibitors in drug discovery: a review of patented compounds","volume":"20","author":"Murumkar","year":"2010","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2019.02.033_b0330","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2013.01.012","article-title":"ADAM17, shedding, TACE as therapeutics targets","volume":"71","author":"Rose-John","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2019.02.033_b0335","doi-asserted-by":"crossref","first-page":"9673537","DOI":"10.1155\/2017\/9673537","article-title":"Recent advances in ADAM17 research: a promising target for cancer and inflammation","volume":"2017","author":"Moss","year":"2017","journal-title":"Mediat. Inflamm."},{"issue":"19","key":"10.1016\/j.bcp.2019.02.033_b0340","doi-asserted-by":"crossref","first-page":"8781","DOI":"10.1016\/j.bmc.2008.08.058","article-title":"Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge","volume":"16","author":"Georgiadis","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0345","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.bmc.2008.03.018","article-title":"Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study","volume":"17","author":"Nakai","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0350","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/acsmedchemlett.8b00163","article-title":"In search of selectivity in inhibition of ADAM10","volume":"9","author":"Mahasenan","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2019.02.033_b0355","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/ar401","article-title":"Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors","volume":"4","author":"Vincenti","year":"2002","journal-title":"Arthritis Res."},{"key":"10.1016\/j.bcp.2019.02.033_b0360","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13075-017-1454-2","article-title":"New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis","volume":"19","author":"Li","year":"2017","journal-title":"Arthrit. Res. Ther."},{"key":"10.1016\/j.bcp.2019.02.033_b0365","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2174\/092986711794940905","article-title":"New hope for the treatment of osteoarthritis through selective inhibition of MMP-13","volume":"18","author":"Li","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0370","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.27596","volume":"62","author":"Settle","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.02.033_b0375","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1021\/acs.jmedchem.5b01434","volume":"59","author":"Ruminski","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0380","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature03417","article-title":"ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro","volume":"434","author":"Stanton","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2019.02.033_b0385","series-title":"Clinical Concepts in Regional Musculoskeletal Illness","first-page":"109","article-title":"Impact loading and lower extremity disease","author":"Malemud","year":"1987"},{"key":"10.1016\/j.bcp.2019.02.033_b0390","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.joca.2015.02.778","article-title":"Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification","volume":"23","author":"Larkin","year":"2015","journal-title":"Osteoarthrit. Cartil."},{"key":"10.1016\/j.bcp.2019.02.033_b0395","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1042\/BJ20040424","article-title":"The ADAMTs metalloproteinases","volume":"386","author":"Porter","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2019.02.033_b0400","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1042\/BJ20151072","article-title":"Anti-ADAMTS5 monoclonal antibodies: implications for aggrecanase inhibition in osteoarthritis","volume":"473","author":"Apte","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2019.02.033_b0405","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1042\/CBI20110150","article-title":"IL-6 and soluble IL-6 receptor stimulate the production of MMPs and their inhibitors via JAK-STAT and ERK-MAPK signalling in human chondrocytes","volume":"36","author":"Aida","year":"2012","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.bcp.2019.02.033_b0410","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/1381612053381747","article-title":"ADAM-integrin interactions: potential integrin regulated ectodomain shedding activity","volume":"11","author":"Bridges","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2019.02.033_b0415","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejcb.2010.11.005","article-title":"The \u201cDisintegrin and Metalloproteases\u201d ADAM10 and ADAM17: novel drug targets with therapeutic potential","volume":"90","author":"Saftig","year":"2011","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.bcp.2019.02.033_b0420","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tibs.2012.12.002","article-title":"Who decides when to cleave an ectodomain?","volume":"38","author":"Hartmann","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bcp.2019.02.033_b0425","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/toxins8040122","article-title":"A disintegrin and metalloprotease (ADAM): historical overview of their functions","volume":"8","author":"Giebeler","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.bcp.2019.02.033_b0430","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejcb.2010.10.007","article-title":"The soluble interleukin-6 receptor: Generation and its role in inflammation and cancer","volume":"90","author":"Chalaris","year":"2011","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.bcp.2019.02.033_b0435","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/108729001750171353","article-title":"ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes","volume":"11","author":"Condon","year":"2001","journal-title":"Antisense Nucl. Acid Drug Dev."},{"key":"10.1016\/j.bcp.2019.02.033_b0440","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1386207053258488","article-title":"Metalloprotease inhibitors for the disintegrin and metalloproteases ADAM10 and ADAM17 that differentially block constitutive and phorbol-ester-inducible shedding from cell surface molecules","volume":"8","author":"Ludwig","year":"2005","journal-title":"Comb. Chem. High Throughput Screen"},{"key":"10.1016\/j.bcp.2019.02.033_b0445","first-page":"1650","article-title":"The Jak-STAT pathway in rheumatoid arthritis","volume":"32","author":"Walker","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0450","first-page":"133","article-title":"Recent advances in neutralizing the IL-6 pathway in arthritis","volume":"1","author":"Malemud","year":"2009","journal-title":"Open Access Rheumatol. Res. Rev."},{"key":"10.1016\/j.bcp.2019.02.033_b0455","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/157436209789057467","article-title":"Targeting JAK\/STAT signaling pathway in inflammatory diseases","volume":"4","author":"Malemud","year":"2009","journal-title":"Curr. Signal Transduct. Ther."},{"key":"10.1016\/j.bcp.2019.02.033_b0460","doi-asserted-by":"crossref","first-page":"9631510","DOI":"10.1155\/2016\/9631510","article-title":"Interleukin-29 enhances synovial inflammation and cartilage degradation in osteoarthritis","volume":"2016","author":"Xu","year":"2016","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.bcp.2019.02.033_b0465","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.joca.2009.11.005","article-title":"MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation \u2013 divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation","volume":"18","author":"Sondergaard","year":"2010","journal-title":"Osteoarthrit. Cartil."},{"key":"10.1016\/j.bcp.2019.02.033_b0470","first-page":"78","article-title":"Dysfunctional immune-mediated inflammation in rheumatoid arthritis dictates that development of anti-rheumatic disease drugs target multiple intracellular signaling pathways. Anti-Inflammatory Anti-Allergy Agents","volume":"10","author":"Malemud","year":"2011","journal-title":"Med. Chem."},{"key":"10.1016\/j.bcp.2019.02.033_b0475","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/s10165-012-0799-2","article-title":"JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical","volume":"23","author":"Tanaka","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0480","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jb\/mvv069","article-title":"Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside","volume":"158","author":"Tanaka","year":"2015","journal-title":"J. Biochem."},{"key":"10.1016\/j.bcp.2019.02.033_b0485","series-title":"Drug Discovery","first-page":"373","article-title":"Suppression of pro-inflammatory cytokines via targeting of STAT-responsive genes","author":"Malemud","year":"2013"},{"key":"10.1016\/j.bcp.2019.02.033_b0490","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4049\/jimmunol.1301906","article-title":"IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages","volume":"192","author":"Kothari","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2019.02.033_b0495","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signaling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.02.033_b0500","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.02.033_b0505","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/259074","article-title":"Relationship between periodontitis and rheumatoid arthritis: review of the literature","volume":"2015","author":"Ara\u03cdjo","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bcp.2019.02.033_b0510","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/RHU.0b013e3180690616","article-title":"Control of periodontal infection reduces the severity of rheumatoid arthritis","volume":"13","author":"Al-Katma","year":"2007","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0515","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1902\/jop.2009.080447","article-title":"Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors","volume":"80","author":"Ortiz","year":"2009","journal-title":"J. Periodont."},{"key":"10.1016\/j.bcp.2019.02.033_b0520","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1573397111666151026223058","article-title":"Arthritis and periodontitis: an association debated for over two centuries","volume":"12","author":"Da Silva","year":"2016","journal-title":"Curr. Rheumatol. Rev."},{"key":"10.1016\/j.bcp.2019.02.033_b0525","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1034\/j.1600-0765.2002.00663.x","article-title":"Regulation of matrix metalloproteinase production by cytokines, pharmacological agents and periodontal pathogens in human periodontal ligament fibroblast cultures","volume":"37","author":"Chang","year":"2002","journal-title":"J. Periodontal Res."},{"key":"10.1016\/j.bcp.2019.02.033_b0530","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/07853890600800103","article-title":"Matrix metalloproteinases, contribution to pathogenesis, diagnosis and treatment of periodontal inflammation","volume":"36","author":"Sorsa","year":"2006","journal-title":"Ann. Med."},{"key":"10.1016\/j.bcp.2019.02.033_b0535","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/science.1181928","article-title":"Platelets amplify inflammation in arthritis via collagen-dependent microparticle production","volume":"327","author":"Boilard","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bcp.2019.02.033_b0540","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00281-017-0631-3","article-title":"Synovial cellular and molecular markers in rheumatoid arthritis","volume":"39","author":"Asif Amin","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bcp.2019.02.033_b0545","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/art.38780","article-title":"Use of cartilage derived from murine induced pluripotential stem cells for osteoarthritis drug screening","volume":"66","author":"Willard","year":"2014","journal-title":"Arthrit. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0550","doi-asserted-by":"crossref","first-page":"595273","DOI":"10.1155\/2015\/595273","article-title":"Study of osteoarthritis treatment with anti-inflammatory drugs: cyclooxygenase-2 inhibitor and steroids","volume":"2015","author":"Cho","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bcp.2019.02.033_b0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044039","article-title":"A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4","volume":"7","author":"Rah","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2019.02.033_b0560","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0962-8924(02)02280-8","article-title":"RECKing MMP function: implications for cancer development","volume":"12","author":"Rhee","year":"2002","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2019.02.033_b0565","first-page":"30","article-title":"Expression of membrane-anchored matrix metalloproteinase inhibitor reversion inducing cysteine rich protein with Kazal motifs in murine cell lines","volume":"29","author":"Takagi","year":"2007","journal-title":"Exp. Oncol."},{"key":"10.1016\/j.bcp.2019.02.033_b0570","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1002\/cncr.11395","article-title":"Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma","volume":"97","author":"Span","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2019.02.033_b0575","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pharep.2017.10.003","article-title":"Exenatide modulates matrix metalloproteinase gene expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway","volume":"70","author":"Gallego-Colon","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bcp.2019.02.033_b0580","doi-asserted-by":"crossref","first-page":"e48272","DOI":"10.1371\/journal.pone.0048272","article-title":"Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent of cannabinoid receptors","volume":"7","author":"Tauber","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.bcp.2019.02.033_b0585","doi-asserted-by":"crossref","first-page":"e29499","DOI":"10.1371\/journal.pone.0028499","article-title":"In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection","volume":"6","author":"Gramegna","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2019.02.033_b0590","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/13543784.2018.1539075","article-title":"Investigational drugs for the treatment of osteoarthritis, an update on recent developments","volume":"27","author":"Zhu","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2019.02.033_b0595","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-4939-7595-2_26","article-title":"Generation of highly selective MMP antibody inhibitors","volume":"1731","author":"Nam","year":"2018","journal-title":"Meth. Mol. Biol."},{"key":"10.1016\/j.bcp.2019.02.033_b0600","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1097\/MIB.0000000000000863","article-title":"Anti-MMP-9 antibody: a promising therapeutic strategy for treatment of inflammatory bowel disease complications with fibrosis","volume":"22","author":"Goffin","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.bcp.2019.02.033_b0605","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/15384047.2016.1177684","article-title":"The ADAMs family of proteases as targets for the treatment of cancer","volume":"17","author":"Mullooly","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2019.02.033_b0610","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/art.37932","article-title":"A matrix metalloproteinase-1 cleavable composite peptide derived from transforming growth factor-\u00df inducible gene h3 potently inhibits collagen-induced arthritis","volume":"65","author":"Nam","year":"2013","journal-title":"Arthrit. Rheum."},{"key":"10.1016\/j.bcp.2019.02.033_b0615","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1124\/jpet.113.205955","article-title":"Novel phosphoinositide 3-kinase \u03b4, \u03b3 inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis","volume":"348","author":"Boyle","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.02.033_b0620","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1742-2094-9-36","article-title":"NOV\/CCN3 attenuates inflammatory pain through regulation of matrix metalloproteinases -2 and -9","volume":"9","author":"Kular","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.bcp.2019.02.033_b0625","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2741\/4365","article-title":"MMP inhibitors: Past, present and future","volume":"20","author":"Cathcart","year":"2015","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.bcp.2019.02.033_b0630","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/bs.pmbts.2017.04.003","article-title":"Matrix metalloproteinase inhibitors as investigational and therapeutic tools in unrestrained tissue remodeling and pathological disorders","volume":"148","author":"Liu","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.bcp.2019.02.033_b0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.02.005","article-title":"Biochemical and biological attributes of matrix metalloproteinases","volume":"147","author":"Cui","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.bcp.2019.02.033_b0640","doi-asserted-by":"crossref","first-page":"R1014","DOI":"10.1186\/ar1771","article-title":"Expression and functional properties of antibodies to tissue inhibitors of metalloproteinases (TIMPs) in rheumatoid arthritis","volume":"7","author":"Bokarewa","year":"2005","journal-title":"Arthrit. Res. Ther."},{"key":"10.1016\/j.bcp.2019.02.033_b0645","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/154405910608501202","article-title":"Tissue inhibitors of metalloproteinases (TIMPs): the biological functions and involvement in oral disease","volume":"85","author":"Verstappen","year":"2006","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.bcp.2019.02.033_b0650","first-page":"1523","article-title":"Serum matrix metalloproteeinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis","volume":"33","author":"Fiedorczyk","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0655","first-page":"44247","article-title":"The role of TIMPs in regulation of extracellular matrix proteolysis","author":"Arpino","year":"2015","journal-title":"Matrix Biol."},{"key":"10.1016\/j.bcp.2019.02.033_b0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164102","article-title":"Robust therapeutic efficacy of matrix metalloprotease-2-cleavable Fas-1-RGD peptide complex in chronic inflammatory arthritis","volume":"11","author":"Nam","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2019.02.033_b0665","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00441-016-2563-y","article-title":"Effect of inhibiting MMP13 and ADAMTS5 by intra-articular injection of small interfering RNA in a surgically induced osteoarthritis model of mice","volume":"368","author":"Hoshi","year":"2017","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bcp.2019.02.033_b0670","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4172\/2155-9899.1000160","article-title":"Intracellular signaling pathways in rheumatoid arthritis","volume":"4","author":"Malemud","year":"2013","journal-title":"J. Clin. Cell Immunol."},{"key":"10.1016\/j.bcp.2019.02.033_b0675","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2217\/ijr.13.31","article-title":"Perspective: Deregulation of apoptosis in arthritis by altered signal transduction","volume":"8","author":"Wylie","year":"2013","journal-title":"Int. J. Clin. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.033_b0680","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4155\/fmc.15.55","article-title":"PI3K\/Akt\/PTEN\/mTOR signaling: a fruitful target for inducing cell death in rheumatoid arthritis?","volume":"7","author":"Malemud","year":"2015","journal-title":"Future Med. Chem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219300814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219300814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:02:58Z","timestamp":1757768578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219300814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":136,"alternative-id":["S0006295219300814"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.02.033","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of MMPs and ADAM\/ADAMTS","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}